Larimar Therapeutics Q3 2026 Earnings Date & Estimates

Larimar Therapeutics (NASDAQ:LRMR) is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria.

Nomlabofusp is being developed to treat Friedreich's ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar's approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Larimar is advancing nomlabofusp toward potential FDA approval. In June 2026, the company submitted the first module of its rolling Biologics License Application (BLA), seeking accelerated approval, with the remaining modules expected to be submitted in the second half of 2026. Larimar also plans to explore additional applications for its protein-delivery technology. Its shares trade on the Nasdaq under the symbol LRMR.